Arrowhead begins triple combination cohort in chronic HBV patients and earns $25 million
Arrowhead Pharmaceuticals announced it has begun dosing in a new triple combination cohort that includes JNJ-3989 and additional undisclosed agents selected by Janssen Pharmaceuticals in its ongoing Phase 1/2 study (AROHBV1001) in patients with chronic hepatitis B virus. April 24, 2019